학술논문

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
Document Type
Article
Source
In: The Lancet Gastroenterology and Hepatology. (The Lancet Gastroenterology and Hepatology, June 2019, 4(6):454-465)
Subject
Language
English
ISSN
24681253